



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 9/00, 9/16, A61P 37/04, A61K 39/02, 39/39		A1	(11) International Publication Number: WO 00/56282 (43) International Publication Date: 28 September 2000 (28.09.00)
<p>(21) International Application Number: PCT/GB00/01108</p> <p>(22) International Filing Date: 23 March 2000 (23.03.00)</p> <p>(30) Priority Data: 9906695.3 24 March 1999 (24.03.99) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; Defence Evaluation and Research Agency, Ively Road, Farnborough, Hampshire GU14 0LX (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): ALPAR, Hazire, Oya [GB/GB]; Aston University, Aston Triangle, Birmingham B4 7ET (GB). WILLIAMSON, Ethel, Diane [GB/GB]; CBD Porton Down, Salisbury, Wiltshire SP4 0JQ (GB). BAILLIE, Leslie, William, James [GB/GB]; CBD Porton Down, Salisbury, Wiltshire SP4 0JQ (GB).</p> <p>(74) Agent: BOWDERY, A., O.; D/IPR, Formalities Section, Poplar 2, MOD Abbey Wood #19, Bristol BS34 8JH (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: PARTICLE BASED VACCINE COMPOSITION</p> <p>(57) Abstract</p> <p>A pharmaceutical composition which comprises microparticles comprising (i) a biologically active compound capable of generating an immune response in an animal to which it is administered which is protective against a pathogen; (ii) a polymeric material capable of forming microspheres; and (iii) an immunostimulant comprising a phospholipid. The composition is particularly useful for the oral administration of vaccines.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Particle Based Vaccine Composition

The present invention relates to compounds for use as immunostimulants, as well as to a composition which is useful 5 for delivering medicaments and particularly vaccines, in particular to mucosal surfaces, for example in oral formulations. The invention further comprises methods of treating individuals using the composition and methods of preparing the composition.

10 A prime objective in the field of vaccination is the development of a non-parenteral immunisation regimen, which facilitate induction of comparable levels of systemic immunity to that elicited by conventional sub-cutaneous and intra-muscular 15 injections.

The nasopharyngeal passages and pulmonary regions of the respiratory tract represent potential targets for the systemic delivery of peptidergic drugs and vaccines. The relative ease 20 with which therapeutic agents can be inhaled, or introduced into the nose, make these modes of immunisation attractive in terms of probable patient compliance. Furthermore, respiratory mucosae offer certain morphological, physiological and immunological advantages over other non-parenteral sites in 25 terms of immunisation, particularly against pathogenic entities which affect or utilise mucosal surfaces as portals of entry. This is because effective vaccination against these pathogens normally requires mucosae to be adequately protected with locally produced antibodies of the secretory IgA (sIgA) 30 isotype. Whilst mucosal surfaces are usually poorly protected with IgA following parenteral administration of vaccines, it is now apparent that successful delivery of antigenic material to immunoresponsive elements in mucosa-associated lymphoid tissue (MALT) can result in vigorous stimulation of the mucosal arm of 35 the immune system. By means of the common mucosal immune system (CMIS) it is feasible that several anatomically disparate

mucosal surfaces could be protected through mucosal administration of a vaccine at a single site. Mucosal vaccination offers the added advantage that some degree of systemic immunity can be induced in concert with local responses 5 due to translocation of antigenic material from sub-epithelial compartments to systemic immunoresponsive tissues such as the spleen.

Despite the logistical and immunological factors which favour 10 non-parenteral immunisation, simple mucosal application of antigenic proteins, for example in the gastrointestinal or respiratory tracts, is usually ineffectual in terms of vaccination. Enzymatic or chemical destruction, combined with poor absorption into sub-epithelial compartments dictate that 15 mucosally administered vaccines usually require some form of adjuvant or delivery vehicle. One approach is to encapsulate antigenic material within microparticulate polymeric carriers, such as poly-DL-lactide (PLA) microspheres (Vaccine 1994, 12, 5-11). Such procedures serve to protect labile vaccines from 20 luminal degradation and enhance absorption into mucosal and systemic compartments (J.H. Eldridge et al., Seminars in Hematology, (1993), 30, 16-25). There is good evidence that microencapsulation may also adjuvantise by converting soluble antigenic molecules into particulate species, thus promoting 25 vaccine uptake into antigen presenting cells (APC) (Y. Tabata et al., Adv. Polym. Sci. (1990), 94, 107-141, L. Vidard et al., J. Immunol. (1996), 156, 2809-2818, N. Van Rooijen, Immunol. Today (1990) 11, 436-439) or microfold cells (M-cells) in lymphoid follicles (R.I. Walker et al., Vaccine, 12, 387, 1994, D.T. 30 O'Hagan et al., Vaccine, 1989, 7, 421-424, P.G. Jenkins et al., J. Drug Targetting, 1995, 3, 79-81). Nasal delivery of microsphere formulation of vaccine has also been described (A.J. Almeida et al., J. Pharm & Pharmacology, 25, 198-203 1993, H.O. Alpar et al., J. Drug Targeting 2/2, 147-149, 1994, A.J. Almeida 35 et al., J. Drug Targeting 3(b), 255-467 1996).

WO 91/06282 describes certain drug compositions which are suitable for intranasal delivery and which include absorption enhancers. Examples of suitable enhancers are lysophosphatidylcholine.

5

The applicants have found that the presence of a phospholipid in a vaccine formulation has an immunostimulant effect, over and above that which could be explained by absorption enhancer effects.

10

Thus the invention provides a phospholipid for use as an immunostimulant.

As used herein, the term "immunostimulant" refers to an adjuvant 15 which stimulates the immune system of a host animal to which it is administered and thereby increases the protective effect produced by a protective antigen administered to that animal, as compared to the effect which would be produced by administration of the protective antigen alone.

20

In particular, it has been noted that a microencapsulated biologically active formulation, especially of immunogens, which comprises a phospholipid in addition to the polymeric material used in the formation of the microparticles, has an 25 increased biological effect. This may be particularly noticed when the formulation is administered by any route including parenteral or other routes, but is particularly effectively when administered by way of a mucosal surface.

30 Thus the invention provides a pharmaceutical composition, which comprises microparticles comprising
(i) biologically active agent which is capable of generating an immune response in an animal to which it is administered;
(ii) a polymeric material capable of forming microspheres; and
35 (iii) an immunostimulant comprising a phospholipid.

In one embodiment, the composition is suitable for parenteral administration. A particular example is intramuscular (i.m.) administration.

5 In a preferred embodiment, the composition is suitable for non-parenteral administration for example to mucosal surfaces.

Administration to mucosal surfaces may be effected by oral application, by pulmonary application, for example by intra-tracheal administration, or particularly by intra-nasal application. In particular, the compositions of the invention are administered by the oral route.

15 The polymeric material used in the compositions of the invention is suitable for forming microparticles (sometimes known as microcapsules or microspheres). It may be a low, medium or high molecular weight polymer. Examples of low molecular weight polymers are polymers which have a molecular weight of between 0.1 and 10kDa, more preferably between 1 and 5 kDa and typically 20 about 2-3kDa.

25 The use of high molecular weight polymers in the encapsulation of a tetanus vaccine for intramuscular administration has been described (Vaccine 1994, 12, 4, 299-306). A formulation of microencapsulated ricin toxoid vaccine which is applied intranasally has also been described (Vaccine 1994, 14, 11 1031). However, in that case, high molecular weight polymer microparticles (94kDa) were less effective than those prepared from a copolymer of lower molecular weight (72kDa).

30 The polymeric material used in the composition of the present invention suitably has a high molecular weight in excess of 94kDa, for example of 100kDa or more.

A particularly suitable polymeric material for use in the compositions of the invention comprises a poly(hydroxy)acid or or a copolymer thereof. A particular example is poly-(L-lactide) or PLA but other high molecular weight 5 polymeric material such as poly(lactic/glycolic acid), polycydonacrylates, polyanhydrides, polycarbonates or polycaprolactones as are known in the art may be employed.

Examples of suitable phospholipids for use in the microparticles 10 of the compositions of the invention include many pharmaceutically acceptable phospholipids or precursors therefore, which may be cationic, anionic or neutral in character. These include lecithin or its precursor phosphoryl choline, distearylphosphatidylcholine (DSPC) and 15 phosphatidylserine (PS). Examples of positively charged lipids include dipalmitoylphosphatidylcholine (DPPC) and dioleoyltrimethylammoniumpropane (DOTAP). A particularly preferred phospholipid is lecithin which is widely available and commonly used in other types of pharmaceutical composition.

20 Suitably the phospholipid is added to the composition in an amount of from 0.1% to 20%w/w, and preferably about 5%w/w.

The microparticles may optionally further comprise agents which 25 stabilise emulsions such as polyvinylalcohol, methyl cellulose or dextrans.

They will suitably be of an average size of from 0.1 μ m to 10 μ m in diameter.

30 These compositions may be used to deliver a biologically active agents which are capable of generating a protective immune response in an animal, particularly a mammal, to which it is administered. Examples of such agents include antigenic 35 polypeptides as well as nucleic acid sequences which may encode these polypeptides and which are known as "naked DNA" vaccines.

As used herein the expression "polypeptide" encompasses proteins or epitopic fragments thereof.

5 Suitable polypeptides are sub-unit vaccines or others such as tetanus toxoid, diphtheria toxoid and *Bacillus anthracis* protective antigen (PA).

In one embodiment, the composition of the invention comprises a 10 biologically active agent which is capable of generating a protective immune response against *Yersinia pestis*. The agent is suitably a sub-unit vaccine, for example as described in WO 96/28551. The vaccine described and claimed there comprises a 15 combination of the V antigen of *Y. pestis* or an immunologically active fragment thereof or a variant of these, and the F1 antigen of *Y. pestis* or an immunologically active fragment thereof or a variant of these.

As used herein, the term "fragment" refers to a portion of the 20 basic sequence which includes at least one antigenic determinant. These may be deletion mutants. One or more epitopic region of the sequence may be joined together.

The expression "variant" refers to sequences of nucleic acids 25 which differ from the base sequence from which they are derived in that one or more amino acids within the sequence are substituted for other amino acids. Amino acid substitutions may be regarded as "conservative" where an amino acid is replaced with a different amino acid with broadly similar 30 properties. Non-conservative substitutions are where amino acids are replaced with amino acids of a different type. Broadly speaking, fewer non-conservative substitutions will be possible without altering the biological activity of the polypeptide. Suitably variants will be at least 60% homologous, 35 preferably at least 75% homologous, and more preferably at least 90% homologous to the base sequence. Homology in this instance

can be judged for example using the algorithm of Lipman-Pearson, with Ktuple:2, gap penalty:4, Gap Length Penalty:12, standard PAM scoring matrix (Lipman, D.J. and Pearson, W.R., Rapid and Sensitive Protein Similarity Searches, *Science*, 1985, vol. 227, 5 1435-1441).

Preferably, vaccine compositions will further comprise a conventional adjuvant in order to increase or enhance the immune response to the biologically active material administered.

10 Suitable adjuvants include pharmaceutically acceptable adjuvants such as Freund's incomplete adjuvant, alhydrogel, aluminium compounds and, preferably adjuvants which are known to up-regulate mucosal responses such as CTB, the non-toxic pentameric B subunit of cholera toxin (CT).

15 They may also comprise other known composition components such as colouring agents and preservatives and in particular cetrimide. These are suitably present in amounts of from 0.1 to 0.7%w/v.

20 In a particular embodiment, the microspheres used in the compositions may further comprise an S-layer proteins, in particular, S-layer proteins derived from a bacteria against which the biologically active agent produces a protective immune 25 response. These proteins are suitably coated onto the surface of the particles. It has been shown (Sleyr et al., Crystalline bacterial cell surface proteins. Biotechnology Intelligence Unit, 1996, R.G. Landes Company and Academic Press Inc.) that the stability of liposomes can be increased by such coatings.

30 S-layer proteins are found on the surface of most bacteria and form a regular two dimensional array known as an S-layer. Isolated S-layer proteins are able to form entropy driven monomolecular arrays in suspension, and on the surface of structures such as liposomes.

Compositions of the invention may be suitable for oral and intranasal application. They are particularly effective when applied orally.

5 They may comprise microparticles per se which are optionally preserved, for example by lyophilisation, or the microparticles may be combined with a pharmaceutically acceptable carrier or excipient. Examples of suitable carriers include solid or liquid carriers as is understood in the art.

10 The invention further provides a method of producing a pharmaceutical composition, which method comprises encapsulating a biologically active agent as described above in a polymeric material which suitably has a high molecular weight and in particular a molecular weight of 100kDa or more, in the presence of a phospholipid such as lecithin. The phospholipid may be incorporated within the microparticle, or at the surface, of preferably is distributed throughout the microparticle.

20 Methods of forming liposomes are well known in the art. They include dispersion of dehydrated lipid films into an aqueous media, emulsion techniques and lyophilisation methods as are well known in the art.

25 Microparticles of the invention are suitably prepared using a double emulsion solvent evaporation method. Briefly, the biologically active agent, in solution or in a suitably lyophilised state, is suspended or dissolved in an aqueous solution of the polymeric material such as polyvinyl alcohol (PVA) and the phospholipid such as lecithin. A solution of the polymer in an organic solvent such as dichloromethane, is added with vigorous mixing. The resultant emulsion is then dropped into a secondary aqueous phase, also containing polymeric (PVA or the like) and optionally also the phospholipid with vigorous stirring. After addition, the organic solvent is allowed to evaporate off and the resultant microspheres separated.

The compositions of the invention will suitably comprise an appropriate dosage unit of the active agent. This will vary depending upon the nature of the active agent being employed, the nature of the patient, the condition being treated and other 5 clinical factors. In general however, the composition of the invention will comprise approximately 0.1 to 10 wt% of active ingredient.

10 The amount of polymer in the composition will be of the order of 70 to 99wt% of the composition, and suitably from 90 to 99wt% of the microparticle components will be the polymeric material. The amount of phospholipid, will be of the order of 0.1 to 10 wt % of the composition.

15 In use, a reasonable dosage for nasal administration would be of from 0.05g to 0.2g. A formulation for oral administration to humans will generally contain, for example, from 0.5 mg to 2 g of active agent within a composition as defined above.

20 Preferred compositions of the inventions are vaccine compositions where the biologically active agent is able to produce a protective immune response to a pathogenic organism as described above. Thus, in a further aspect, the invention provides a method of protecting a mammal against infection, 25 which method comprises administration of a vaccine composition as described above to mammal. In particular, the composition is applied to a mucosal surface, in particular gastrointestinal surface, of a mammal.

30 The applicants have shown that through the oral administration of tetanus toxoid in accordance with the present invention, antibody titres were achieved which are in excess of those associated with protection from the relevant toxin, and protection to a subcutaneous challenge of tetanus toxoid was 35 provided.

A further aspect of the invention comprises the use of a phospholipid as an immunostimulant in the production of a vaccine for use in prophylactic or therapeutic treatment.

5 The invention will now be particularly described by way of example with reference to the accompanying drawings in which:

Figure 1 illustrates the serum immune response in mice to orally delivered microencapsulated and free tetanus toxoid with 50 lf 10 units on day 1, 3, 5 and boosted on day 28, 30 and 50;

Figure 2 illustrates the serum immune response after 86 days; and

15 Figure 3 illustrates the serum immune response after 162 days following a subcutaneous "mock challenge" with tetanus toxoid.

Example 1

20 Microencapsulation of Tetanus toxoid

Poly-L-lactide of molecular weight 100kDa (Polysciences Inc. USA) was used in a modification of the double emulsion solvent evaporation method (Y. Ogawa et al., Chem. Pharm. Bull., 36 (1988) 1095-1103). Briefly, 1.5ml of a 1.5% w/v aqueous 25 solution of polyvinyl alcohol (PVA) (13-25k) containing tetanus toxoid (4000Lf units) was prepared. This formed the aqueous phase. An organic phase was prepared separately by mixing with 200mg of 100K PLA polymer dissolved in 5ml of HPLC grade dichloromethane (DCM) with 5%w/w lecithin. The two phases were 30 homogenised together using a Silverson homogeniser (Silverson, UK) for 1 minute. The resultant primary emulsion was added, drop by drop, into a secondary aqueous phase (75ml) comprising 1.5%w/v PVA and 0.1%w/v lecithin. The mixture was then 35 homogenised using a Silverson homogeniser for 5 minutes. This secondary phase was gently stirred overnight to until the dichloromethane had evaporated. Microspheres were recovered by

centrifugation, washed with double distilled water three times and then lyophilised.

5 other microspheres using 10%w/w lecithin instead of the 5%w/w solution were prepared using a similar procedure (10% LEC PLA MS). Further microspheres where the lecithin was omitted entirely from the preparation were also prepared by an analogous method but 5% w/w lecithin was used instead of water alone for the oral administration of microspheres (PLA MS in 5% LEC).

10 In addition, this method was used to prepare comparative microspheres where the lecithin in the primary emulsion was replaced by either 5% w/w or 10%w/w saponin (SAP) or 10% w/w or 15 20% w/w stearyl amine (SA) and lecithin omitted from the preparation entirely. Finally, PLA microspheres without any adjuvant were prepared.

Example 2

Immunisation Study

20 Groups of three Balb/c female mice were orally dosed with the microspheres prepared in Example 1 containing 50LF tetanus toxoid on days 1, 3 and 5 of the trial, and boosted on day 28 and 30. Another group of mice was orally dosed with similar amounts of tetanus toxoid but in free solution.

25 Serum immune responses were monitored. Tail vein blood samples were taken from all animals on days 14 and 35 of the experiment. Titration of IgG antibody isotypes in serum samples was achieved using an ELISA. Briefly, individual serum samples were 30 aliquoted to microtitre plates pre-coated with tetanus toxoid. Binding of serum antibody was detected with peroxidase-labelled secondary antibody to mouse IgG (Sigma A4416). Antibody titre was estimated as the maximum dilution of the serum giving an absorbance reading greater than the maximum optical density (OD) 35 of titrated naïve serum. From this, mean titres \pm standard deviation (SD) were derived per treatment group.

At day 162, the immune responses following a subcutaneous "mock challenge" with TT as monitored.

5 The results are shown in Figures 1-3. In these Figures, the following letters represent compositions prepared as described above as follows:

- (a) 5% lecithin containing PLA microsphere composition;
- (b) 10% lecithin containing PLA microsphere composition;
- 10 (c) PLA microspheres in the presence of 5% lecithin;
- (d) 5% w/w saponin containing microsphere composition;
- (e) 10%w/w saponin (SAP) containing microsphere composition;
- (f) 10% w/w stearyl amine (SA) containing microsphere composition;
- 15 (g) 20% w/w stearyl amine (SA) containing microsphere composition;
- (h) PLA microspheres;
- (i) PLA microspheres in milk;
- (j) PLA micropheres which have been sonicated;
- 20 (k) Free tetanus toxoid.

Microsphere formulations containing lecithin showed an amplification of > 3000 as compared to free tetanus toxoid and other microsphere formulations. Microspheres which contained no 25 lipid in a phospholipid vehicle gave similar results to the free tetanus toxoid.

Even after 86 days of the dosing and following the s.c. challenge at day 162, titres were above the protective titre 30 levels (Figures 2 and 3) when formulations in accordance with the invention were employed.

Claims

1. A pharmaceutical composition which comprises microparticles comprising
 - 5 (i) a biologically active compound capable of generating an immune response;
 - (ii) a polymeric material capable of forming microspheres ; and
 - (iii) an immunostimulant comprising a phospholipid.
- 10 2. A composition according to claim 1 which is adapted for administration to a mucosal surface.
- 15 3. A composition according to claim 2 which is adapted for oral administration.
- 20 4. A composition according to any one of the preceding claims wherein the polymeric material is a high molecular weight polymer.
- 25 5. A composition according to claim 4 wherein the polymeric material has a molecular weight of 100kDa or more.
6. A composition according to any one of the preceding claims wherein the polymeric material comprises a poly(hydroxy)acid or 25 or a copolymer thereof.
- 30 7. A composition according to any one of the preceding claims wherein the phospholipid is selected from lecithin or its precursor phosphoryl choline, distearylphosphatidylcholine (DSPC) and phosphatidylserine (PS).
8. A composition according to claim 7 wherein the phospholipid is lecithin.
- 35 9. A composition according to any one of the preceding claims which contains from 0.1% to 20% w/w phospholipid.

10. A composition according to claim 9 wherein the amount of phospholipid is about 5%w/w.

11. A composition according to any one of the preceding claims 5 wherein the biologically active compound capable of generating an immune response in an animal to which it is administered comprises a polypeptide or a nucleic acid.

12. A composition according to claim 11 wherein the 10 biologically active agent comprises tetanus toxoid, diphtheria toxoid, *Bacillus anthracis* protective antigen (PA) or an agent which is capable of generating a protective immune response against *Yersinia pestis*.

15 13. A composition according to claim 11 or claim 12 which further comprises a conventional adjuvant in order to increase the immune response to the biologically active material administered.

20 14. A composition according to any one of the preceding claims which further comprises a preservative.

15. A composition according to claim 14 wherein the preservative is cetrimide and this is present in amounts of from 25 0.1 to 0.7%w/v.

16. A composition according to any one of the preceding claims wherein the microspheres used in the compositions may further comprise an S-layer proteins.

30 17. A composition according to claim 16 wherein the biologically active agent is as defined in claim 10 and wherein the S-layer proteins are derived from a bacteria against which the biologically active agent produces a protective immune 35 response.

18. A composition according to any one of the preceding claims wherein the microspheres are suspended in a diluent or carrier.

19. A composition according to any one of the preceding claims 5 wherein the ratio of the polymeric material to the phospholipid is from 99:1 to 9:1% w/w.

20. A method of producing a pharmaceutical composition according to claim 1, which method comprises encapsulating a 10 biologically active agent which is capable of generating a protective immune response, in a polymeric material, in the presence of a phospholipid.

21. A method according to claim 20 wherein the phospholipid is 15 distributed throughout the microparticle.

22. A method according to claim 20 or claim 21 wherein the composition comprises a prophylactic or therapeutic vaccine.

23. A method of protecting a mammal against infection by a 20 pathogen, which method comprises administration of a composition according to any one of claims 1 to 19 wherein the biologically active material is able to generate a protective immune response against said pathogen, to a mammal.

24. A method according to claim 23 wherein the composition is 25 applied to a mucosal surface of said mammal.

25. A method according to claim 24 wherein the mucosal surface 30 comprises a gastrointestinal surface.

26. The use of a phospholipid in the production of a microsphere for use in the composition according to claim 1.

27. A phospholipid for use as an immunostimulant.

28. The use of a phospholipid as an immunostimulant in the production of a vaccine for use in prophylactic or therapeutic treatment.

Fig. 1.




Fig.2.





Fig.3.



INTERNATIONAL SEARCH REPORT

Int. Jonal Application No
PCT/GB 00/01108A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/00 A61K9/16 A61P37/04 A61K39/02 A61K39/39

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 15636 A (CSL LTD ;COX JOHN COOPER (AU); SPARKS ROBERT EDWARD (US); JACOBS I) 21 July 1994 (1994-07-21)	1-9, 11-13, 18-23, 26,27
Y	page 4, line 30 -page 5, line 19 page 10, line 13 - last line example 5 claims 8-18	16,17

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- "&" document member of the same patent family

Date of the actual completion of the international search

30 June 2000

Date of mailing of the international search report

19/07/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/01108

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	O'HAGAN D T ET AL: "Intravaginal immunization in sheep using a bioadhesive microsphere antigen delivery system." VACCINE, vol. 11, no. 6, 1993, pages 660-664, XP002141394 ISSN: 0264-410X page 660, column 2, last line -page 661, column 1, line 14 page 661, column 2, line 18 - line 25 page 663, column 2, line 44 - line 49 page 664, line 10 - line 16	1-4, 11, 18, 26-28
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; STURESSON, C. ET AL: "Preparation and characterization of hydrophobic PLG microspheres suitable for oral vaccination with rotavirus" retrieved from STN Database accession no. 125:230587 XP002141396 abstract page 515, column 1, line 1 - line 3 page 151, column 1, paragraph 12 - paragraph 18 page 151, column 1, last paragraph page 516, column 2, paragraph 1 - paragraph 2 & PROC. INT. SYMP. CONTROLLED RELEASE BIOACT. MATER. (1996), 23RD, 515-516 ,	1-6, 9, 20-27
X	ALONSO MARIA J ET AL: "Determinants of release rate of tetanus vaccine from polyester microspheres." PHARMACEUTICAL RESEARCH (NEW YORK), vol. 10, no. 7, 1993, pages 945-953, XP000915016 ISSN: 0724-8741 page 945, column 1, paragraph 1 -column 2, paragraph 1 page 946, column 1, last paragraph; table 1 page 946, column 2, paragraph 3 page 950, column 1, last paragraph -column 2, paragraph 1	1-6, 9, 11, 12, 18, 20-23, 26, 27
Y	WO 97 28263 A (LUBITZ WERNER ;SLEYTR UWE (AT); KUEN BEATRIX (AT); TRUPPE MICHAELA) 7 August 1997 (1997-08-07) page 9, line 19 - line 29; claims 25, 26	16, 17
		-/-

INTERNATIONAL SEARCH REPORT

Int'l. Jpnal Application No

PCT/GB 00/01108

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 372 949 A (KODAMA YUTAKA ET AL) 8 February 1983 (1983-02-08) column 1, line 12 - line 13 column 1, line 25 - line 46 column 1, line 54 - line 57 _____	27,28
X	O'HAGAN D T ET AL: "Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein." JOURNAL OF GENERAL VIROLOGY, (1992 AUG) 73 (PT 8) 2141-5., XP002141395 page 2142, column 1, paragraph 2 page 2143, column 1, paragraph 3 - paragraph 4 _____	27,28

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Jonal Application No
PCT/GB 00/01108

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9415636	A 21-07-1994	AU 667003	B	29-02-1996
		AU 5805394	A	15-08-1994
		CA 2152949	A	21-07-1994
		EP 0678035	A	25-10-1995
		JP 8505152	T	04-06-1996
		NZ 259285	A	26-07-1996
WO 9728263	A 07-08-1997	DE 19603649	A	07-08-1997
		AU 713999	B	16-12-1999
		AU 1720397	A	22-08-1997
		CA 2245584	A	07-08-1997
		CN 1213402	A	07-04-1999
		EP 0882129	A	09-12-1998
		JP 2000503850	T	04-04-2000
		NZ 331300	A	29-06-1999
US 4372949	A 08-02-1983	JP 1010501	B	22-02-1989
		JP 1526549	C	30-10-1989
		JP 55118419	A	11-09-1980
		JP 1205058	C	11-05-1984
		JP 56049322	A	02-05-1981
		JP 58040929	B	08-09-1983
		BE 882048	A	04-09-1980
		CA 1145260	A	26-04-1983
		DE 3008082	A	18-09-1980
		FR 2450608	A	03-10-1980
		GB 2046092	A,B	12-11-1980
		IT 1145357	B	05-11-1986
		NL 8001292	A	09-09-1980
		SE 459228	B	19-06-1989
		SE 8001685	A	20-10-1980

